TMTara L MacDonald

Tara L MacDonald

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tara L MacDonald has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Lee-Papastavros

    Section for Islet Cell and Regenerative Biology, Joslin Diabetes Center , Boston, MA 02215

    1 shared publication
  • Celia Vived

    Section for Islet Cell and Regenerative Biology, Joslin Diabetes Center , Boston, MA 02215

    1 shared publication
  • Jéssica Aparecida da Silva Pereira

    Section for Islet Cell and Regenerative Biology, Joslin Diabetes Center , Boston, MA 02215

    1 shared publication
  • Peng Yi

    Islet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Stem Cell Institute, Harvard Medical School, Boston, USA

    1 shared publication

Latest Publications

  • β Cell Stress and Endocrine Function During T1D: What Is Next to Discover?

    by Celia Vived, Alexander Lee-Papastavros, Jéssica Aparecida da Silva Pereira, Peng Yi, Tara L MacDonald

    Canonically, type 1 diabetes (T1D) is a disease characterized by autoreactive T cells as perpetrators of endocrine dysfunction and β cell death in the spiral toward loss of β cell mass, hyperglycemia, and insulin dependence. β Cells have mostly been considered as bystanders in a flurry of autoimmune processes. More recently, our framework for understanding and investigating T1D has evolved. It appears increasingly likely that intracellular β cell stress is an important component of T1D etiology/pathology that perpetuates autoimmunity during the progression to T1D. Here we discuss the emerging and complex role of β cell stress in initiating, provoking, and catalyzing T1D. We outline the bridges between hyperglycemia, endoplasmic reticulum stress, oxidative stress, and autoimmunity from the viewpoint of intrinsic β cell (dys)function, and we extend this discussion to the potential role for a therapeutic β cell stress-metabolism axis in T1D. Lastly, we mention research angles that may be pursued to improve β cell endocrine function during T1D. Biology gleaned from studying T1D will certainly overlap to innovate therapeutic strategies for T2D, and also enhance the pursuit of creating optimized stem cell-derived β cells as endocrine therapy.